Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease

(2021) Matthew Rosebraugh et al.   ANNALS OF NEUROLOGY

Epidemiology of skin event rates among users of pumps for the subcutaneous administration of drugs for chronic conditions

(2021) Susan S. Jick et al.   CURRENT MEDICAL RESEARCH AND OPINION

Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study

(2020) C. Warren Olanow et al.   Journal of Parkinsons Disease

Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial

(2018) Regina Katzenschlager et al.   LANCET NEUROLOGY

Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features

(2018) K. Ray Chaudhuri et al.   MOVEMENT DISORDERS

Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale

(2017) Krisztina Horváth et al.   MOVEMENT DISORDERS

Non-motor features of Parkinson disease

(2017) Anthony H.V. Schapira et al.   NATURE REVIEWS NEUROSCIENCE

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa

(2017) Ahmed A. Othman et al.   Journal of Parkinsons Disease

The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study

(2016) K. M. Prakash et al.   EUROPEAN JOURNAL OF NEUROLOGY

Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients

(2016) Angelo Antonini et al.   MOVEMENT DISORDERS

Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program

(2015) P. Odin et al.   PARKINSONISM & RELATED DISORDERS

On the Nature of Fear of Falling in Parkinson’s Disease

(2014) S. Rahman et al.   BEHAVIOURAL NEUROLOGY

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results

(2014) Hubert H. Fernandez et al.   MOVEMENT DISORDERS

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease

(2013) C. Warren Olanow et al.   MOVEMENT DISORDERS

Late-stage Parkinson disease

(2012) Miguel Coelho et al.   Nature Reviews Neurology

Determination of minimal clinically important change in early and advanced Parkinson's disease

(2011) Robert A. Hauser et al.   MOVEMENT DISORDERS

A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation

(2010) Angelo Antonini et al.   JOURNAL OF NEUROLOGY

The scientific and clinical basis for the treatment of Parkinson disease (2009)

(2009) C. W. Olanow et al.   NEUROLOGY